We are supplying ALDH^br cells for use in investigator-sponsored clinical studies that we expect will provide additional information about the mechanism of action of ALDH^br cells, effective routes of administration of these cells and product safety.

In one ongoing Phase 1 clinical trial, investigators at Duke are treating patients with ALD-151, a population of ALDH^br cells produced by sorting cord blood, as an agent to possibly improve engraftment following cord blood transplants used to treat leukemia.  See study details

Investigators at Duke have also received clearance from the FDA to begin a Phase 1 clinical trial of ALD-601, a different formulation of ALDHbr cells sorted from cord blood, to treat inherited metabolic diseases through in utero stem cell transplantation.  See study details